Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders having a high influence on social interactions. The number of approved treatments and clinical trials for ADHD have increased markedly during the recent decade. This analytical review provides a quantitative overview of the existing pharmacological and non-pharmacological methods of ADHD treatments investigated in clinical trials during 1999–2021. A total of 695 interventional trials were manually assessed from clinicaltrial.gov with the search term « ADHD», and trial data has been used for analysis. A clear majority ...
Source: Frontiers in Pharmacology - November 17, 2022 Category: Drugs & Pharmacology Source Type: research
The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder
Conclusions
Brexpiprazole might be effective in ADHD adults who are nonresponders to 2 or more stimulants. Future trials in treatment-resistant ADHD should use a 1:1 randomization and use a measure of ADHD symptoms that includes emotional dysregulation. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Original Contributions Source Type: research
5.7 comparative bioavailability and safety of a novel trimodal dexmethylphenidate tablet in adhd patients
The primary objectives of this study were to compare the bioavailability of 2 dexmethylphenidate (d-MPH) formulations, CTx-1301 (trimodal tablet) vs Focalin XR (biphasic capsule), and to demonstrate the dose proportionality of the CTx-1301. The secondary objectives were to characterize the pharmacokinetics and evaluate the safety. (Source: Journal of the American Academy of Child and Adolescent Psychiatry)
Source: Journal of the American Academy of Child and Adolescent Psychiatry - October 1, 2020 Category: Psychiatry Authors: Matthew Brams, Raul Silva Source Type: research
When to Raise Our White Flag—A Discussion of Scope of Practice in a Resource Scarce World
CASE:
Thomas is a 13-year-old boy with autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), generalized anxiety disorder, separation anxiety disorder, and major depressive disorder who presented for a follow-up to his developmental and behavioral pediatrician (DBP). His mother describes an increase in symptoms of anxiety and depression for the last 6 weeks, accompanied by suicidal ideation and thoughts of self-mutilation.
Before this increase in symptoms, he had been doing well for the last several months with the exception of increasing weight gain, and Abilify was decreased from 5 mg to 2.5 mg at...
Source: Journal of Developmental and Behavioral Pediatrics - February 1, 2020 Category: Child Development Tags: Challenging Case Source Type: research
Drugs for ADHD
Date: January 27, 2020
Issue #:
1590Summary:
Attention-deficit/hyperactivity disorder (ADHD) is a
chronic neurodevelopmental disorder that has been
diagnosed in up to 10% of school-age children in the
US and frequently persists into adulthood. A study in
a large Danish cohort found that ADHD was associated
with higher mortality rates in children, adolescents,
and adults, mainly due to accidents. Pharmacologic
treatment of ADHD in children has been reported to
decrease the risk of substance abuse in adolescents,
and use of ADHD medications in adults has been
associated with a redu...
Source: The Medical Letter - January 2, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Adderall Adhansia ADHD Adzenys Amphetamine Aptensio Atomoxetine Biphentin Clonidine Concerta Cotempla daytrana Dexedrine Dexmethylphenidate Dextroamphetamine Dyanavel Evekeo Focalin Foquest Guanfacine Intuniv Jorn Source Type: research
Jornay PM - Evening-Dosed Methylphenidate for ADHD
Date: August 12, 2019
Issue #:
1578Summary:
The FDA has approvedJornay PM (Ironshore), a
capsule formulation of methylphenidate with a
delayed-release outer layer and an extended-release
inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients>6
years old.Jornay PM is the first methylphenidate
product to become available in the US that is taken
in the evening; other long-acting methylphenidate
formulations are taken in the morning. It is being
marketed specifically for patients who have disruptive
ADHD symptoms in the morning. (Sou...
Source: The Medical Letter - July 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Adhansia ADHD Aptensio Biphentin Concerta Contempla daytrana Dexmethylphenidate Focalin Foquest Jornay PM QuiliChew Quilivant Ritalin Source Type: research
Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD
Date: November 6, 2017
Issue #:
1533Summary:
The FDA has approved an extended-release orally
disintegrating tablet formulation of methylphenidate
(Cotempla XR-ODT– Neos Therapeutics) for once-daily
treatment of attention-defi cit/hyperactivity
disorder (ADHD) in children 6-17 years old.Cotempla XR-ODT is the first extended-release orally
disintegrating tablet formulation of methylphenidate
to become available in the US. (Source: The Medical Letter)
Source: The Medical Letter - October 30, 2017 Category: Drugs & Pharmacology Authors: admin Tags: ADHD Aptensio Concerta Contempla daytrana Dexmethylphenidate Focalin methyphenidate QuiliChew Quilivant Ritalin Source Type: research
First Person
Patient #1, the Partier: arrives at 0730, 6-year-old boy with history of extreme prematurity, developmental delay, and extreme hyperactivity. When asked if his Focalin had been taken that morning (obviously not!), mom replied, “Yes … uh … no … it's in the car!” Grandmother stumbled into the room part way into the exam, clearly intoxicated. Said child then proceeds to start wildly swinging some Mardi Gras beads as he runs around the room. Mother threatens to send the little fellow home with the doctor, who replies, “Oh no, I don't think that's a good idea.” The tech is heard to mutter under her breath that we ...
Source: Journal of AAPOS - April 1, 2014 Category: Opthalmology Tags: Major Articles Source Type: research
Trends in attention deficit hyperactivity disorder drugs consumption, Israel, 2005–2012
ConclusionsThere has been a drastic rise in ADHD drugs consumption in Israel over 2005–2012. This has been associated with substantial reduction in cost and changes in the pattern of prescribing that characterized by increased prescription of high‐dose long‐acting preparations of ADHD drugs and decreased prescription of their low‐dose, short‐acting formulations. Copyright © 2014 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - March 1, 2014 Category: Drugs & Pharmacology Authors: Alexander M. Ponizovsky, Eli Marom, Israel Fitoussi Tags: Original Report Source Type: research
